1

1 Brief Communication

2 Early Life Safety Profiling of Gene Therapy for Spinal Muscular Atrophy: A Case Series Analysis

- 3 Rebecca G. Spellman^{1,2}, Leillani L. Ha^{1,2}, Salomé Da Silva Duarte Lepez^{1,2}, Elizabeth A. Arruda^{1,2}, Emma
- 4 Rodrigues^{1,2}, Kathryn J. Swoboda^{1,2,3,*}, Christiano R. R. Alves^{1,2,3,*}
- 5
- 6 ¹Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- 7 ² Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
- 8 ³ Department of Neurology, Harvard Medical School, Boston, MA, USA
- 9 *Equal contribution and co-corresponding authors: <u>katswobo@gmail.com</u> and <u>calves2@mgh.harvard.edu</u>

2

11 Abstract

12 The present study examines the safety profile of intravenous on asemnogene abeparvovec gene therapy in 13 a real world setting, both alone or in combination with intrathecal antisense oligonucleotide nusinersen 14 therapy in two cohorts of patients with spinal muscular atrophy (SMA). The first cohort included 8 15 presymptomatic infants treated solely with onasemnogene abeparvovec, while the second cohort 16 comprised 6 symptomatic infants receiving onasemnogene abeparvovec and nusinersen co-therapy. All 17 patients received the corticosteroid prednisolone coincident with gene therapy. Circulating alanine 18 aminotransferase (ALT) and aspartate transaminase (AST) levels were measured to determine potential 19 hepatoxicity, the primary focus of this study. Elevated ALT and AST levels, but no change in GGT levels 20 were observed in 1 pre-symptomatic and 3 symptomatic patients post-treatment. However, all values 21 normalized within three months of onasemnogene abeparvovec injection. Nusinersen treatment received 22 previously or coincident with gene therapy did not impact the elevation of liver transaminases, which was 23 transient. This study highlights the importance of early intervention with molecular treatments for SMA and 24 indicates that prior or coincident treatment with nusinersen is unlikely to impact safety of onasemnogene 25 apoparvovec and could theoretically improve clinical outcomes in symptomatic infants or in those with gene 26 therapy delayed beyond the immediate neonatal period.

27

28 Keywords: Neuromuscular diseases; SMA; Neurogenetics; Hepatotoxicity.

29 Introduction

30 Molecular therapies have demonstrated remarkable clinical benefits when administered during the pre-31 symptomatic or early symptomatic stages of spinal muscular atrophy (SMA), significantly improving survival 32 rates even among the most severely affected infants¹. In 2016, nusinersen (Spinraza, Biogen) became the 33 first molecular therapy approved for SMA, and numerous studies have since confirmed its efficacy and 34 safety across various SMA populations^{2,3}. In 2019, the U.S. Food and Drug Administration (FDA) approved 35 onasemnogene abeparvovec (Zolgensma, Novartis/AVXS-101, AveXis), a gene therapy using an adeno-36 associated virus vector to deliver the SMN1 gene through a single intravenous injection in newborns and 37 infants with SMA. Recent clinical trials have validated the effectiveness of onasemnogene abeparvovec in 38 both pre-symptomatic and symptomatic infants, showing significant motor function improvements^{4–6}. Over 39 the past three years, this has largely become the treatment of choice for monotherapy in newborns with 40 homozygous SMN1 deletion, regardless of SMN2 copy number. While gene therapy is a transformative 41 treatment for SMA, varying adverse effects are observed: most commonly categorized as mild or moderate 42 in severity these adverse events need to be closely monitored⁴⁻⁶. Despite limited data on the safety or long 43 term outcomes of sequential overlapping or combinatorial treatment, there is an increasing number of 44 infants receiving dual or sequential therapy with gene therapy and either nusinersen or risdiplam, an issue 45 not adequately addressed yet in published clinical trials or studies. One of the potentially largest adverse 46 impact on long term efficacy of gene therapy treatment in newborns with 2 SMN2 copies are the delays 47 inherent in obtaining preauthorization, approval, and required preliminary safety testing prior to 48 administration of AAV-9 mediated gene therapy. For a proportion of newborns, their catabolic state, variable 49 transition to appropriate weight gain and social factors in the critical post-partum period, immediate dosing 50 post birth may be neither ideal nor feasible. Thus adequate processes for rapid initiation of an alternative 51 molecular therapy need to be standardized, and would ideally include overlapping coverage through the 52 duration of the viral transduction process post dosing with AAV9-mediated intravenously delivered gene 53 therapy.

The most common adverse effect reported with onasemnogene abeparvovec gene therapy is elevated liver enzyme levels, which can indicate acute liver injury^{7,8}. In clinical practice, these elevated levels are usually managed effectively with co-administration of prednisolone, a corticosteroid hormone^{8,9}. Clinical trials have

4

57 demonstrated that initiating prednisolone 48 hours prior to gene therapy dosing and adjusting as needed 58 for 2-3 months while closely monitoring liver function can successfully avoid serious medical 59 consequences¹⁰. However, further longitudinal research is needed to fully understand the implications and 60 risk of serious consequences at the extremes of age and weight not included in clinical trials.

61 Combinatorial therapies for SMA patients could be used more strategically to facilitate maximum rescue of 62 at-risk motor neurons and other tissues¹¹. The current approach in the clinical setting in the U.S. has been 63 to choose one therapy, and then only consider adding another therapy if the first therapy proves to have 64 insufficient benefit. In newborns identified by newborn screening, timing of gene therapy initiation is 65 variable, but not infrequently delayed several weeks. In an infant with 2 SMN2 copies, this could lead to 66 substantial progression of motor neuron denervation. Nusinersen and onasemnogene abeparvovec act via 67 different molecular mechanisms and display different delivery effectiveness. Nusinersen loading has been 68 associated with dramatic and persistent drop in neurofilament levels in 2 copy infants, and has a long half 69 life that could persist through the gene therapy dosing and transduction process. Thus, in a presymptomatic 70 clinical cohort of infants with 2 SMN2 copies, we hypothesize that sequential administration of nusinersen 71 and onasemnogene abeparvovec could present a synergic effect in these vulnerable SMA infants, without 72 the need to continue long term combinatorial therapy. In already symptomatic 2 copy infants, near 73 simultaneous dosing at the earliest opportunity, as demonstrated in the cohort included here, could 74 maximize survival of the greatest number of at risk motor neurons and help ensure maximal transduction 75 efficacy. Here, we report for the first time a comprehensive safety dataset including the levels of circulating 76 liver enzymes from SMA cases receiving treatment with only onasemnogene abeparvovec, and SMA cases 77 receiving combinatorial therapy with nusinersen and onasemnogene abeparvovec in their first months of 78 life.

79

80 Methods

This is a longitudinal cohort study including a total of 14 SMA newborns or infants treated in the first months of life at the Massachusetts General Hospital (MGH), including 8 infants who received treatment with onasemnogene abeparvovec and 6 infants who received combinatorial treatment with nusinersen and then

5

84 onasemnogene abeparvovec. All patients received prednisolone 48 hours prior to onasemnogene 85 abeparvovec dosing and continued for 2-3 months post dosing as per standard of care. None of these 86 patients were receiving risdiplam (Evrysdi, Roche). Of note, all patients receiving only onasemnogene 87 abeparvovec were treated early in life at the pre-symptomatic stage, while all patients receiving co-therapy 88 with nusinersen and onasemnogene abeparvovec in this study demonstrated clinical symptoms at dosing. 89 The primary outcomes of this study are circulating alanine aminotransferase (ALT) and aspartate 90 transaminase (AST) levels measured as biomarkers of potential hepatoxicity. In addition to the absolute 91 values, the fold change from the baseline (i.e. measurements taken before injection) ALT and AST levels 92 were also calculated for each individual patient and presented. Circulating gamma-glutamyl transferase, 93 troponin T-hs Gen 5 (Troponin T), white blood counts, platelets and albumin levels were also determined 94 as secondary outcomes along with any clinical adverse effect manifestation. Reference normal ranges were 95 determined based on MGH laboratory references. Reference values from the Mayo Clinic and the University 96 of California San Francisco (UCSF) Children's are also provided. SMN1 and SMN2 copy numbers were 97 determined using quantitative polymerase chain reaction as previously described¹². All other outcomes 98 were obtained from the clinical laboratory in association with research visits in the SPOT SMA Longitudinal 99 Pediatric Data Repository (LPDR) housed within the Research Electronic Data Capture Web Application at 100 the Newborn Screening Translational Research Network¹³. Written informed parental consent was obtained 101 from all participants under Institutional Ethics Review Board at the MGH (protocol #2016-P000469). 102 Distribution of age range and sex are presented in Table 1.

103

104 <u>Results</u>

We determined circulating ALT and AST levels in two cohorts of SMA patients receiving gene therapy early in life (**Table 1**). The first cohort included 8 SMA infants ages 20 – 190 days old treated at the presymptomatic stage. They received only onasemnogene abeparvovec treatment (**Figures 1A-H**). The second cohort included 6 SMA infants and 1 child who received both nusinersen and onasemnogene abeparvovec (**Figures 2A-F**). Only 1 of 8 presymptomatic infants dosed with onasemnogene abeparvovec had elevated circulating ALT and AST levels, occurring within a few days post injection (**Figure 1B**),

6

111 showing a 20-fold change in ALT and 9-fold change in AST (Figure 3A-B, 3E-F). This specific case was a 112 subject with 3 SMN2 copies. Importantly, increased ALT and AST levels returned to normal within 3 months 113 after the injection (Figure 1B, 3A-B, 3E-F). For the second cohort including symptomatic patients with 2 114 SMN2 copies, we observed 3 out of 6 cases with elevated circulating ALT and AST levels post 115 onasemnogene abeparvovec injection (Figure 2A-F). Two patients showed similar changes, both 116 displaying about a 4.5-fold increase in ALT and a 4-to-7-fold increase in AST. Another patient showed a 117 28-fold change in ALT and 6-fold change in AST from baseline (Figure 3C-D, 3E-F). Of note, this patient 118 was also the oldest dosed patient. Increased ALT and AST levels also returned to normal levels around 3 119 months after the injection and were maintained at normal ranges during follow-up (Figure 2A, 2C, 2E, 3C-120 D, 3E-F). Taken together, these data closely parallel previously published clinical trial data demonstrating 121 that some infants with SMA experience transient hepatotoxicity after gene therapy even when prednisolone 122 is co-administered, but these effects are transient and typically return to normal by three months. 123 Importantly, all enrolled patients had normal albumin levels and no indications of malnutrition or chronic 124 liver disease (Table 2 and Supplementary Table 1).

125 As complementary analysis, we observed increased levels of troponin T and platelets in most of the SMA 126 infants and children (Table 2 and Supplementary File 1), indicating potential myocardial injury and 127 thrombocytosis. These increased levels are most likely part of the natural course of SMA pathophysiology 128 since they were not observed as a direct consequence of any therapy. Other measurements such as 129 circulating white blood counts and platelets also demonstrated some specific values out of normal range 130 during this longitudinal follow-up study, but did not clearly correlate with treatment (Table 2 and 131 Supplementary File 1). Moreover, we observed multiple mild or moderate clinical events during the follow 132 up of this study, but only 4 patients treated with either gene therapy or co-therapy showed at least one 133 severe adverse event related to a cardiac, respiratory, or nutritional issue (Table 3). These adverse events 134 were managed in hospital visits. They were not clearly associated with treatment response, and were 135 considered most likely related to the primary underlying diagnosis. Altogether, these findings validate 136 previous evidence showing that patients with SMA need to be closely monitored after transformative gene 137 therapy is administered in the real world clinical setting.

7

139 **Discussion**

140 Taking advantage of our longitudinal database (MGH SPOT SMA LPDR) that includes SMA cases treated 141 early in life with onasemnogene abeparvovec, we were able to evaluate several markers related to the 142 safety of gene therapy. Our findings indicate that some SMA patients can present hepatotoxicity within a 143 few days after receiving the gene therapy. More drastic changes in ALT and AST values were notably 144 observed in patients dosed with gene therapy at an older age in the second cohort in contrast to the first 145 cohort whose age at dosing was younger on average, reemphasizing the importance of initiating therapy in 146 2 SMN2 copy infants at the earliest opportunity. These effects are transient and return to normal levels 147 within three months post injection. Corroborating these single center observations, a study combining data 148 from 5 previous clinical trials has observed liver-related adverse events in 34% of SMA patients treated 149 with gene therapy⁷. Variable liver response to the gene therapy was also clearly observed in the original 150 trial establishing the single-dose gene therapy for SMA and emphasized the importance of co-treatment 151 with oral prednisolone to mitigate immune-mediated hepatotoxicity⁸. Prednisolone doses can be adjusted 152 when necessary in each specific SMA case⁸. Here, we observed a total of 4 SMA cases suggesting at least 153 transient liver injury in spite of prednisolone treatment, but without any evident long-lasting consequences.

154 We report longitudinal safety data from 6 symptomatic SMA cases with only 2 SMN2 copies that have been 155 treated with co-therapy with onasemnogene abeparvovec and nusinersen. These patients are achieving 156 motor milestones that were not expected in the natural history of the disease and the present data also 157 suggest that side effects of these therapies are transient and can be controlled by closely monitoring each 158 patient. These results demonstrate the safety for sequential and coincident nusinersen therapy during the 159 induction process for gene therapy. Nusinersen treatment administered pre-gene therapy treatment 160 theoretically provides an advantage over risdiplam, given its prolonged treatment effect following an initial 161 loading period. However, we did not examine the impact or safety of sequential or coincident treatment with 162 risdiplam in this study, and thus our conclusions are limited. In line with our findings, another recent study 163 including 2 SMA cases that received co-therapy with nusinersen and onasemnogene abeparvovec also 164 reported no apparent increased burden of adverse effects¹¹. This possibility of combining therapies for SMA 165 patients has presented itself as particularly interesting for the SMA community. Based on our current data, 166 we advocate for additional studies analyzing different outcomes in SMA patients receiving co-therapies and

8

an open discussion about the advantages and disadvantages of combining these treatments. We hypothesize that there is limited to no benefit in continuing a second therapy once gene therapy has been delivered in a truly presymptomatic infant with 2 copies. However, there may be in an infant with some evident denervation and an emerging clinical phenotype. In our experience, progressive denervation can sometimes occur quite precipitously in a 2 copy infant between ordering and dosing gene therapy. Thus, biomarkers such as CMAP, MUNE, or robust serum biomarkers must be integrated into the current clinical paradigm since clinical exam and even functional motor tests remain insufficient for this purpose.

174 We observed increased troponin T and variable platelet levels in SMA patients, which are markers of 175 increased risk for myocardial injury and thrombocytosis. While damage in motor neurons accounts for the 176 earliest manifestations in SMA infants, evidence indicates that other tissues contribute to the SMA 177 pathophysiology due to the direct effects of SMN deficiency in tissues other than motoneurons, or indirect 178 effects due to the severe denervation status^{14,15}. In this context, a multidisciplinary approach is critical to 179 monitor and provide the best care for SMA patients. Markers assessed in the current study corroborate the 180 premise of systemic disease manifestation and highlight the importance of close monitoring for emergence 181 of disease phenotypes beyond muscle denervation.

182 In summary, this case series analysis study highlights the importance of early intervention with gene therapy 183 and other molecular treatments for SMA and the need for close monitoring of treatment responses beyond 184 muscle denervation in the real world clinical setting.

185

186 Data Availability Statement

187 All data relevant to this study are contained within the manuscript.

188

- 189 Acknowledgements
- 190 We are grateful to all the patients and families who participated in this study.

191

192 Author Contributions

9

- 193 K.J.S. and C.R.R.A. directed the research project. R.G.S., S.D.L., E.A.A., E.R., and K.J.S. collected clinical
- data. R.G.S., L.L.H., S.D.L., E.A.A., E.R., K.J.S., and C.R.R.A. analyzed the data and participated in the
- data interpretation. L.L.H., K.J.S. and C.R.R.A. drafted the manuscript. All authors reviewed and approved
- 196 the final manuscript.
- 197
- 198 Funding
- 199 C.R.R.A. received a fellowship from the MGH ECOR. K.J.S. was funded by NIH NICHD R01HD054599,
- 200 NIH NINDS R21NS108015, Biogen, and Cure SMA.
- 201

202 Ethical Approval

- 203 Ethical approval and written informed parental consent were obtained from all participants under 204 Institutional Ethics Review Boards at the Massachusetts General Hospital (protocol 2016P000469).
- 205

206 Competing Interests

- 207 K.J.S. was a recipient of a grant from Biogen and received clinical trial funding from AveXis and Biogen.
- 208 C.R.R.A is a consultant for Biogen. The other authors declare no competing interests.

10

210 References

- 211 1. Groen, E. J. N., Talbot, K. & Gillingwater, T. H. Advances in therapy for spinal muscular atrophy:
- promises and challenges. *Nat. Rev. Neurol.* **14**, 214–224 (2018).
- 213 2. Finkel, R. S. et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N.
- 214 Engl. J. Med. **377**, 1723–1732 (2017).
- 215 3. Hagenacker, T. *et al.* Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional,
- 216 multicentre, observational cohort study. *Lancet Neurol.* **19**, 317–325 (2020).
- 4. Strauss, K. A. *et al.* Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2
- at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. *Nat. Med.* 28, 1381–1389
- 219 (2022).
- 220 5. Strauss, K. A. et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of
- SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. *Nat. Med.* 28, 1390–1397
 (2022).
- 223 6. Day, J. W. *et al.* Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal
- 224 muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm,
- 225 multicentre, phase 3 trial. *Lancet Neurol.* **20**, 284–293 (2021).
- 226 7. Chand, D. *et al.* Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101)
- for the treatment of spinal muscular atrophy. J. Hepatol. **74**, 560–566 (2021).
- 8. Mendell, J. R. *et al.* Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N. Engl. J. Med.* 377, 1713–1722 (2017).
- 9. Al-Zaidy, S. A. & Mendell, J. R. From Clinical Trials to Clinical Practice: Practical Considerations for
 Gene Replacement Therapy in SMA Type 1. *Pediatr. Neurol.* **100**, 3–11 (2019).
- Mendell, J. R. *et al.* Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene
 Abeparvovec in Spinal Muscular Atrophy. *JAMA Neurol.* 78, 834 (2021).
- Lee, B. H. *et al.* Combination therapy with nusinersen and AVXS-101 in SMA type 1. *Neurology*93, 640–641 (2019).
- 236 12. Prior, T. W. *et al.* A Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene. *Am. J. Hum.*
- 237 Genet. **85**, 408–413 (2009).

- 238 13. Alves, C. R. R. *et al.* Implications of circulating neurofilaments for spinal muscular atrophy
- treatment early in life: A case series. *Mol. Ther. Methods Clin. Dev.* 23, 524–538 (2021).
- 240 14. Lipnick, S. L. et al. Systemic nature of spinal muscular atrophy revealed by studying insurance
- 241 claims. *PLOS ONE* **14**, e0213680 (2019).
- 242 15. Nery, F. C. *et al.* Impaired kidney structure and function in spinal muscular atrophy. *Neurol.*
- 243 *Genet.* **5**, e353 (2019).

12

246 Figure Legends

247

Figure 1. Circulating alanine aminotransferase (ALT) and aspartate transaminase (AST) levels in a cohort of SMA patients treated at the pre-symptomatic stage with onasemnogene abeparvovec. Blue line indicates the day of injection. Colored background area indicates normal concentrations expected in sex-matched controls.

252

Figure 2. Circulating alanine aminotransferase (ALT) and aspartate transaminase (AST) levels in a cohort of SMA patients treated with nusinersen and onasemnogene abeparvovec. Blue line indicates the day of onasemnogene abeparvovec injection. Red line indicates the initial nusinersen dose for each case. Colored background area indicates normal ALT and AST concentrations expected in sex-matched controls. Note: Case #9 has initiated nusinersen treatment more than 125 days before the onasemnogene abeparvovec dose.

259

Figure 3. Fold change of circulating alanine aminotransferase (ALT) and aspartate transaminase (AST) levels in SMA patients treated with onasemnogene abeparvovec or with nusinersen and onasemnogene abeparvovec. a-b, Cohort receiving onasemnogene abeparvovec monotherapy. c-d, Cohort receiving nusinersen and onasemnogene abeparvovec co-therapy. e-f, Both cohorts displayed together in the same plot. AST and ALT were normalized based on the baseline (pre treatment) for each patient.

266

Supplementary Information. The Excel table consists of a comprehensive set of safety lab data for each
 patient. Reference values for each lab measurement were annotated from Mayo Clinic and UCSF Benioff
 Children's Hospital.

Subject	Sex	Age range at dosing (days)					
Onasemnoger	ne abeparvovec mono	therapy in presymptomatic newborns and infants up to \sim 6 months of age (n = 8)					
1	F	31-35					
2	Μ	21-25					
3	F	16-20					
4	F	81-85					
5	F	36-40					
6	Μ	186-190					
7	F	101-105					
8	Μ	171-175					
Combinatori	al therapy with onaser	nnogene abeparvovec (AVXS) and nusinersen in a symptomatic cohort (n = 6)					
9	F	Nusinersen: 71-75 AVXS: 936-940					
10	F	Nusinersen: 91-95 AVXS: 96-100					
11	F	Nusinersen: 46-50 AVXS: 141-145					
12	Μ	Nusinersen: 76-80 AVXS: 81-85					
13	М	Nusinersen: 16-20 AVXS: 26-30					
14	М	Nusinersen: 6-10 AVXS: 96-100					

Table 1. Information of patients with SMA receiving onasemnogene abeparvovec early in life.

Subject	SMN2 (copies)	GGT (U/L)	Troponin T (ng/L)	WBC (K/uL)	Platelets (K/uL)	Albumin	HGB (g/dL)	CK (U/L)	CK-MB (ng/mL)	No. of Adverse Events
						(g/dL)				
	Onase	emnogene	abeparvovec m	onotherapy in pr	resymptomatic	newborns an	nd infants up	to ~ 6 months	of age (n = 8)	
1	2	14-66	Not tested	6.58-13.16	346-497	3.7-4.8	10.5-13.2	125-618	8.5-32.8	9 (1 SAE
2	2	10	<50	10.8-11.2	371-378	3.9-4.4	14.1-14.7	Not tested	Not tested	1
3	3	12-76	5	10.40-13.50	365-730	3.8-4.7	9.7-13.7	40-154	3.8-7.1	4
4	3	11-29	7-29	7.06-11.6	319-446	3.7-4.4	9.8-12.1	49-168	3.2-5.9	0
5	3	7-13	<6-25	13.44-19.85	347-609	3.7-4.5	11.2-12	79-82	Not tested	10
6	4+	11-26	7-28	5.61-10.82	422-914	4.0-4.8	8.9-14.3	188	5.8	0
7	3	7-16	6-7	6.02-9.56	363-407	4.2-4.4	10.4-12	95-211	4.4-10.8	9
8	4+	18-34	8-21	3.96-7.48	181-333	4.3-4.6	11.5-12.7	229	10.8	1
	Combir	natorial the	erapy with onase	emnogene abepa	arvovec (AVXS) and nusiner	rsen in a sym	ptomatic coho	rt (n = 6)	
9	2	7-72	19-61	7.23-13.11	156-541	3.5-4.7	9.5-14.8	54-74	5.2-7.9	8 (2 SAE:
10	2	5-50	33-82	9.74-14.72	318-541	4.1-4.9	10.6-12.9	106-248	9.9	5 (1 SAE
11	2	6-18	60	6.75-13.50	316-476	4.2-4.7	10.9-13.2	105-150	15.4	16
12	2	8-46	41-90	5.71-10.85	289-423	4.0-5.1	11-14	126-148	15.5-24.6	8
13	2	4-22	42-61	7.07-11.9	267-799	3.3-4.7	9.4-13.8	160-141	Not tested	9 (3 SAE:

Table 2. Clinical characteristics of patients with SMA receiving onasemnogene abeparvovec early in life.

GGT: Gamma-glutamyl transferase; Troponin T: Troponin T-hs Gen 5; WBC; White blood cell count. SAE: severe adverse event

	Mild/Moderate	Severe/Hospital Visit Needed	Total	<u>%</u>
Fever	8	1	9	11.4%
GI	9		9	11.4%
Cardiac/Acute life				
threatening	1	1	2	2.5%
Respiratory	6	3	9	11.4%
Orthopedic	5		5	6.3%
Nutritional	1	1	2	2.5%
Other	39	4	43	54.4%
TOTAL AEs	69	7	79	
%	87.3%	8.9%		

Table 3. Summary of adverse events (AEs) in patients with SMA receiving onasemnogene abeparvovec early in life.





